Mechanism of Damage Tolerance by Nonhomologous End Joining
Mechanism of Damage Tolerance by Nonhomologous End Joining
批准号:
9258650
负责人:
Michael Patrick Conlin
金额:
$2.95万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-02-01 至 2019-01-31
关键词:
AddressAffectAgingBiologicalCancer EtiologyCatalytic DomainCell DeathCell LineCell RespirationCellsCellular AssayChromosome abnormalityComplexDNADNA DamageDNA lesionDNA polymerase muDNA-Directed DNA PolymeraseDataDefectDeoxyribonucleotidesDevelopmentDouble Strand Break RepairEffectivenessEmployee StrikesEmploymentGenomeGenomic InstabilityImmune systemImmunologic Deficiency SyndromesIn VitroIonizing radiationKnowledgeLIG4 geneLeadLigaseLigationMammalsMeasuresMeiosisMetabolismMethodsMutationNucleotidesOrganismOxidesPathway interactionsPredispositionProcessRNARadiation ToleranceReactionResearchRibonucleotidesRoleSafetyShapesSiteSpecificityStructureSystems DevelopmentTherapeutic AgentsTimeVariantcancer cellcancer therapycell injurychemotherapeutic agentcytotoxicityexperimental studyimprovedinsightkillingsmutantnervous system disorderradiosensitivereconstitutionrepairedresponsetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary / Abstract
Double strand breaks (DSBs) are lethal DNA lesions that arise during meiosis, immune system
development, and cancer therapy. Ionizing radiation (IR) and some chemotherapeutics kill tumors by inducing
DSBs, which can have associated end damage that blocks repair. Repair of damaged ends is important
because it shapes the efficiency and safety of cancer therapy. However, previous DSB repair research has
focused on undamaged breaks. The proposed research will determine the mechanisms of damaged end repair
by nonhomologous end joining (NHEJ), the predominant DSB repair pathway in mammals.
The ultimate step in NHEJ is the ligation of ends by DNA Ligase IV (Lig4); I have shown that it is more
likely than other pathways to join damaged ends. Lig4 functions only in the context of the NHEJ complex so it
is unclear whether damage tolerance is intrinsic to the ligase. I hypothesize that Lig4 is a specialized damaged
end ligase, and this activity is important for the response to cancer therapy. I am creating variants of Lig4 that
separate function in vitro: they efficiently repair undamaged, but not damaged breaks. I will generate cell lines
expressing these Lig4 variants and measure repair of damaged DSB ends. I will expose these cell lines to
chemotherapeutic agents and ionizing radiation to determine if Lig4 damaged end repair is important for the
response to cancer therapy. I will determine whether NHEJ capacity on damaged ends corresponds to
radiosensitivity and chemoresistance in cells. These results will show whether Lig4 damaged end repair is a
potentially druggable target to improve existing cancer therapies.
Some damaged ends must be processed prior to repair. One processing factor is DNA polymerase mu,
which fills in gaps at DSB ends. Surprisingly, pol mu preferentially adds ribonucleotides (RNA), rather than
deoxyribonucleotides (DNA), to DNA ends. Preliminary data suggests that these ribonucleotides stimulate Lig4
activity, but it is unclear when and why this happens. I hypothesize that ribonucleotides added by pol mu
facilitate Lig4 tolerance of damaged ends. I will identify when ribonucleotides are important for damaged end
repair. Then, I will generate variants of Lig4 that abolish its stimulation by ribonucleotides.
My results will reveal
the biological significance of this startling repair phenomenon which introduces RNA into the genome.
Many cancer therapies rely on damaged double strand breaks to kill cancer cells with specificity. The
proposed research will provide mechanistic insight into the poorly understood process of damaged DSB repair.
We will also identify requirements for damaged DSB repair that can be targeted to improve the effectiveness of
cancer therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金